BioAffinity highlights paper on new flow cytometry method

By The Science Advisory Board staff writers

August 13, 2021 -- BioAffinity Technologies is highlighting results from a research study using a flow cytometry method it has developed.

Published in the Journal of Visualized Experiments, the results show that the company's CyPath technology is an "efficient and effective" method to analyze sputum using flow cytometry, allowing for the development of diagnostic tests for lung cancer and other lung diseases, according to the company.

CyPath is a platform technology used to diagnose cancer, and the company's first product is CyPath Lung, a noninvasive test for the early detection of lung cancer that allows patients to collect their sputum sample at home.

Copyright © 2021

Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter